|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
||||||||||||||||||||||||||||||||||||
| Descriptive Information Fields | |||||
| Brief Title † | A Study of AT1001 in Patients With Fabry Disease | ||||
| Official Title † | A Phase 2, Open-Label, Multicenter, Ascending-Dose, 12-Week Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AT1001 in Patients With Fabry Disease | ||||
| Brief Summary | The purpose of this study is to determine whether AT1001 (migalastat hydrochloride) is safe and effective in patients with Fabry disease. |
||||
| Detailed Description | This open-label study will be conducted in up to 20 patients at five clinical sites in the United States. Patients will undergo a 28-day screening period, including a 14-day run-in with AT1001 to assess eligibility for the study. Patients receiving enzyme replacement therapy or substrate depletion therapy for Fabry disease must undergo a 2-week washout of prior therapy before the 28-day screening period. Patients will receive a daily dose of AT1001 for 12 weeks during the treatment phase. The pharmacokinetics of AT1001 in plasma and urine will be assessed at regular intervals. Safety will be evaluated throughout the treatment period. At the end of the 12-week treatment period, the effect of AT1001 on pharmacodynamic parameters (alpha-Gal A in leukocytes, GL-3 in plasma and urine, and alpha-Gal A and GL-3 in skin biopsy samples) and functional parameters (cardiac function as assessed by electrocardiogram, echocardiogram, and MRI, and renal function as assessed by blood and urine tests, and nerve conduction as assessed by QSART and CASE IV tests) will be evaluated. If the safety profile is acceptable, patients will be permitted to enter a 36-week treatment extension period and continue to receive AT1001, with safety, pharmacodynamic, and functional assessments performed at 12-week intervals. |
||||
| Study Phase | Phase II | ||||
| Study Type † | Interventional | ||||
| Study Design † | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study | ||||
| Primary Outcome Measure † | Safety and tolerability of 3 dose levels of oral AT1001 | ||||
| Secondary Outcome Measure † | Pharmacokinetics of 3 dose levels of oral AT1001 Pharmacodynamic effects of oral AT1001 (effects on enzyme and substrate levels, cardiac function, renal function, and nerve conduction) |
||||
| Condition † | Fabry Disease | ||||
| Intervention † | Drug: AT1001 (migalastat hydrochloride) | ||||
| MEDLINE PMIDs | |||||
| Links | |||||
| Recruitment Information Fields | |||||
| Recruitment Status † | Completed | ||||
| Enrollment † | 20 | ||||
| Start Date † | September 2005 | ||||
| Completion Date | January 2008 | ||||
| Eligibility Criteria † | Inclusion Criteria:
Exclusion Criteria:
|
||||
| Gender | Male | ||||
| Ages | 18 Years to 55 Years | ||||
| Accepts Healthy Volunteers | No | ||||
| Contacts †† | |||||
| Location Countries † | United States | ||||
| Administrative Information Fields | |||||
| NCT ID † | NCT00214500 | ||||
| Organization ID | AA1565520 (FAB-CL-201) | ||||
| Secondary IDs †† | |||||
| Study Sponsor † | Amicus Therapeutics | ||||
| Collaborators †† | |||||
| Investigators † |
|
||||
| Information Provided By | Amicus Therapeutics | ||||
| Verification Date | June 2008 | ||||
| First Received Date † | September 13, 2005 | ||||
| Last Updated Date | June 4, 2008 | ||||